Tensions stemming from the U.S.-China trade war escalated sharply over the last few days, with much happening as Asian markets were shut down for the weekend.China Economyread more
The latest round of tariff announcements in the last few days means that by the end of the year, essentially all Chinese goods exported to the U.S. will be subject to duties.China Economyread more
Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
China said Friday it will be resuming 25% duties on U.S. autos, and a further 5% on auto parts and components.Asia Marketsread more
World leaders, environmental groups and celebrities have publicly decried the vast swaths of forest being destroyed by the fires.World Newsread more
Education Minister Ong Ye Kung says the Singapore government has been preparing for the challenge of an aging workforce "for the past 20 years."Employmentread more
Stocks in Asia fell Monday morning following an escalation in the U.S.-China trade war late last week.Asia Marketsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Analysts at Citi upgraded shares of Dow-component Merck to buy from neutral, noting they expect strong sales from its Keytruda drug.
Keytruda is an immunotherapy drug used in cancer treatments. Citi increased its peak Keytruda sales forecast on the drug to $16 billion from $9 billion.
"Merck's success with Keytruda has clearly outperformed our initial expectations which were based on Merck's historic absence as a major oncology player," analyst Andrew Baum said in a note to clients Wednesday.
The analyst raised Merck to buy from neutral. The shares rose as much as 1.4 percent before closing 0.46 percent higher at $63.51.
"While competitors have clearly sought to learn from Merck, the breadth and depth of Keytruda' s clinical trial program and boldness to commit significant capital to promising external modalities ... gives it a likely sustained significant advantage, we believe," Baum said.
Citi also raised its price target on Merck to $72 from $65, implying 13 percent upside for the stock. Merck shares closed at $63.22 on Tuesday.
Merck's stock is up 7.4 percent year to date, underperforming against the Dow Jones industrial average, which has risen 16.4 percent.